A clinical trial at the Georgia Cancer Center at Augusta University featuring a homegrown discovery is drawing kids from other prestigious cancer centers across the country. These children are being treated with Indoximod, an inhibitor of the enzyme known as IDO, whose role in inhibiting an immune response was first discovered at the Medical College of Georgia in 1998 by a team of researchers led by Drs. David Munn and Andrew Mellor.
The trial also was helped by the arrival of another homegrown product in Dr. Ted Johnson, who got his MD/Ph.D from MCG in 2004 and had Mellor as his advisor when he was doing his doctoral thesis on IDO. His preclinical work on brain tumors and IDO helped set up the trial, and Johnson also received grant funding to move the trial forward.
Read the full story.